Primary Cutaneous CD30+ Lymphoproliferative Disorders: New Insights Into Biology and Therapy
April 30, 2007ByChristiane Querfeld, MD, PhD|Timothy M. Kuzel, MD|Joan Guitart, MD|Steven T. Rosen, MD
The spectrum of CD30+ lymphoproliferative diseases of the skin includes CD30+ cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis, as well as borderline cases. These entities constitute the second most common group of cutaneous lymphomas according to the newly revised World Health Organization and European Organisation for Research and Treatment of Cancer consensus classification. Recent progress in immune and molecular biology, and identification of therapeutic targets have increased our understanding of these diseases and have led to novel treatment approaches. This review will provide an update on recent findings of immunologic, molecular, cytogenetic features and treatment strategies for patients with CD30+ lympho-proliferative diseases.